How did SCPH's Q1 2024 EPS outperform forecasts?

ScPharmaceuticals Inc. (SCPH) reported a negative diluted EPS of $0.36 for Q1 2024, which is below the zero point and indicates a loss for the period. However, this result does not necessarily mean that the company's performance was poor compared to forecasts since the context of the forecast is not provided. For a comprehensive evaluation, we need to consider the following points:

1. **Revenue Growth**: SCPH reported a 24% increase in net revenue from the second quarter of 2024, reaching $10 million. This is a positive indicator, suggesting that the company's revenue performance was strong despite the negative EPS.
2. **Strategic Developments**: The company has been actively pursuing strategic initiatives, such as expanding indications for their product FUROSCIX. These developments could potentially lead to increased revenue in the future.
3. **Financial Position**: SCPH completed a public offering of common stock, raising net proceeds of $53.5 million. This infusion of capital provides the company with financial flexibility to invest in growth opportunities and manage its expenses.

In conclusion, while SCPH's Q1 2024 EPS was negative, the company's revenue growth and strategic positioning, along with its strong financial position, suggest that the company's performance may have been in line with or even exceeded internal forecasts. The context of the forecast is not provided, so a direct comparison is not possible, but the company's positive revenue trajectory and strategic initiatives indicate a favorable outlook.